Pinxin Bio

Hunan Pinxin Bioengineering Co., Ltd. was established in September 2013 and is located in Changsha National High-tech Industrial Development Zone. It was initiated by high-level innovative and entrepreneurial talents of Changsha High-tech Zone and an enterprise science and technology innovation and entrepreneurship team of Hunan Province, and founded by relying on the scientific research teams of top universities such as Central South University and Wuhan University and the resources of senior industry experts, focusing on the applied research of artificial intelligence technology in the medical industry. The company has a full set of qualifications for the research and development, production, and sales of medical devices. Its R&D center is equipped with multiple GPU servers, imported high-power microscopes, and other high-end R&D equipment, has 1,000 square meters of R&D space, and is equipped with a Class 10,000 microbial laboratory and a Class 100,000 clean workshop, providing good foundational conditions for the platform. After ten years of meticulous work, the company has now developed into an innovative high-tech enterprise integrating R&D, production, sales, and service, and has gathered a group of high-level scientific and technological talents in specialties such as bioengineering, computer science, image recognition, mechanical manufacturing, pathology, and automation. The company focuses on intelligent detection of cell morphology and, through the dual-wheel drive of "AI + digital medicine," provides complete automated and intelligent solutions for the early screening and diagnosis of various diseases. Its R&D products and core technologies have obtained 44 authorized patents, 6 software copyrights, and 6 trademark registrations, participated in the formulation of 1 industry standard, and had 4 Class II medical device products and 22 Class I medical device products approved with CFDA registration certificates. In particular, the company's leading product, the "TBS + DNA Dual Intelligent Tumor Early Screening Auxiliary Diagnosis System," is in a leading position in the domestic and even international liquid-based cytology pathological diagnosis industry. The company's products have served nearly 400 large benchmark hospitals, with a domestic market share of 30%, and have completed clinical validation in key domestic top-tier tertiary hospitals, such as Beijing Chest Hospital affiliated to Capital Medical University, Xiangya Second Hospital, Hunan Provincial People's Hospital, Shaanxi Provincial People's Hospital, the Fourth Hospital of Hebei Medical University, Shandong Weifang Maternal and Child Health Hospital, Shanxi Peking University Medical Lu'an Hospital, and Chongqing Maternal and Child Health Hospital, as well as third-party medical laboratories such as Lanwei Medical, Fudan Pathology, ADICON Testing Center, KingMed Diagnostics, Ningbo Meikang Medical Laboratory, and Shanghai Hengdao Medical Pathology Diagnosis Center. Hunan Pinxin Bioengineering Co., Ltd. has long been engaged in applied research on AI technology in the medical industry. The company attaches importance to scientific research and has successively established a postdoctoral scientific research mobile station, an engineering research center, and an enterprise technology center. The two intelligent analysis instruments developed in the early stage adopt artificial intelligence technology to realize intelligent analysis of cervical cells, pleural and peritoneal fluid, sputum, tissue sections, etc. The products have entered the market and been applied in clinical use for millions of samples, accumulating a tens-of-millions-level medical database and a large amount of medical industry resources, providing unique advantages for the establishment of the "platform." On the basis of insisting on independent research and development, the company has established a good industry-university-research cooperation mechanism with well-known domestic universities and scientific research institutions such as Central South University, led and participated in a number of core project research and product development, effectively improved the company's technical research capabilities, and enhanced its core technology competitiveness.